Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Solid Tumors|Mycosis Fungoides|Melanoma|Merkel-cell Carcinoma|Squamous Cell Carcinoma|Breast Carcinoma|Human Papillomavirus-Related Malignant Neoplasm|Soft Tissue Sarcoma
Interventions: DRUG: TTI-621 Monotherapy|DRUG: TTI-621 + PD-1/PD-L1 Inhibitor|DRUG: TTI-621 + pegylated interferon-α2a|OTHER: TTI-621 + T-Vec|OTHER: TTI-621 + radiation
Sponsor: Pfizer